Phase I trial of the oral smoothened inhibitor sonidegib in combination with paclitaxel in patients with advanced solid tumors

Vismodegib or cixutumumab in combination with standard chemotherapy for patients with extensive-stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E1508)

(2016) Chandra P. Belani et al.   CANCER

A phase I trial of the Hedgehog inhibitor, sonidegib (LDE225), in combination with etoposide and cisplatin for the initial treatment of extensive stage small cell lung cancer

(2016) M. Catherine Pietanza et al.   LUNG CANCER

A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma

(2016) Andrew H. Ko et al.   PANCREAS

Bevacizumab Combined With Weekly Paclitaxel, Pegylated Liposomal Doxorubicin, or Topotecan in Platinum-Resistant Recurrent Ovarian Cancer: Analysis by Chemotherapy Cohort of the Randomized Phase III AURELIA Trial

(2015) Andres M. Poveda et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer

(2015) Daniel V.T. Catenacci et al.   JOURNAL OF CLINICAL ONCOLOGY

Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial

(2015) Michael R Migden et al.   LANCET ONCOLOGY

A Phase I Study of PF-04449913, an Oral Hedgehog Inhibitor, in Patients with Advanced Solid Tumors

(2014) A. J. Wagner et al.   CLINICAL CANCER RESEARCH

Phase I Dose-Escalation Trial of the Oral Investigational Hedgehog Signaling Pathway Inhibitor TAK-441 in Patients with Advanced Solid Tumors

(2014) J. Goldman et al.   CLINICAL CANCER RESEARCH

A Phase I, Multicenter, Open-Label, First-in-Human, Dose-Escalation Study of the Oral Smoothened Inhibitor Sonidegib (LDE225) in Patients with Advanced Solid Tumors

(2014) J. Rodon et al.   CLINICAL CANCER RESEARCH

Phase I Study of the Hedgehog Pathway Inhibitor IPI-926 in Adult Patients with Solid Tumors

(2013) A. Jimeno et al.   CLINICAL CANCER RESEARCH

A Randomized Phase II Trial of Vismodegib versus Placebo with FOLFOX or FOLFIRI and Bevacizumab in Patients with Previously Untreated Metastatic Colorectal Cancer

(2012) J. Berlin et al.   CLINICAL CANCER RESEARCH

Smoothened Antagonists Reverse Taxane Resistance in Ovarian Cancer

(2012) A. D. Steg et al.   MOLECULAR CANCER THERAPEUTICS

Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma

(2012) Aleksandar Sekulic et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Utility of Hedgehog Signaling Pathway Inhibition for Cancer

(2012) S. Sahebjam et al.   ONCOLOGIST

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

Experience in a UK cancer centre of weekly paclitaxel in the treatment of relapsed ovarian and primary peritoneal cancer

(2008) M. Linch et al.   GYNECOLOGIC ONCOLOGY

Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer and Leukemia Group B Protocol 9840

(2008) Andrew D. Seidman et al.   JOURNAL OF CLINICAL ONCOLOGY